Your browser doesn't support javascript.
loading
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.
Müller-Wieland, Dirk; Rader, Daniel J; Moriarty, Patrick M; Bergeron, Jean; Langslet, Gisle; Ray, Kausik K; Manvelian, Garen; Thompson, Desmond; Bujas-Bobanovic, Maja; Roth, Eli M.
Afiliação
  • Müller-Wieland D; Department of Medicine I, University Hospital, RWTH Aachen University, Aachen, Germany.
  • Rader DJ; Department of Medicine and Genetics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennysylvania.
  • Moriarty PM; Department of Internal Medicine, Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, Kansas.
  • Bergeron J; Clinique des Maladies Lipidiques, Department of Medicine, Centre Hospitalier Universitaire de Québec - Université Laval, Québec, Canada.
  • Langslet G; Lipid Clinic, Oslo University Hospital, Oslo, Norway.
  • Ray KK; Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, United Kingdom.
  • Manvelian G; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Thompson D; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Bujas-Bobanovic M; Sanofi, Paris, France.
  • Roth EM; The Sterling Research Group and University of Cincinnati, Cincinnati, Ohio.
J Clin Endocrinol Metab ; 104(11): 5253-5262, 2019 11 01.
Article em En | MEDLINE | ID: mdl-31166599
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 2 / Anticorpos Monoclonais Humanizados / Hipercolesterolemia / Anticolesterolemiantes Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 2 / Anticorpos Monoclonais Humanizados / Hipercolesterolemia / Anticolesterolemiantes Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article